The Mito-Frail Trial: Effects of MitoQ on Vasodilation, Mobility and Cognitive Performance in Frail Older Adults
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age65-80
SponsorUConn Health
About this trial
The goal of this clinical trial is to test the effects of MitoQ supplementation in older adults and frail older adults with physical dysfunction and/or cognitive dysfunction. The main question\[s\] it aims to answer are:
* To compare vascular function, oxidative stress levels, and physical and cognitive function among older adults and frail older adults with physical and cognitive dysfunction * To determine whether MitoQ supplementation has the potential to improve vascular function in central and cerebral vessels * To determine whether MitoQ supplementation can enhance physical and cognitive capabilities.
Eligibility criteria
Qualifiers
men and women aged 65-80 with a slow gait speed (0.4m/s based on a 4m walk) and/or mild cognitive impairment.
good cardiovascular health (not taking any blood pressure/flow/metabolism altering medications)
Disqualifiers
A vaccination in past two weeks
Recent acute infection three weeks prior to enrollment
Known immunodeficiency (including HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
Use of medicines during past 6 months known to alter immune response such as high- dose corticosteroids
Trial design
Treatments tested in this trial
- Mitoquinone Mesylate
- Placebo capsule
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
UConn Health
Lead sponsor
University of Connecticut
Sponsor institution
National Institute on Aging (NIA)
Collaborator
University of Connecticut
Collaborator
Source ClinicalTrials.gov